These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

513 related items for PubMed ID: 21760569

  • 1. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium.
    Ortega F, Sánchez-Fructuoso A, Cruzado JM, Gómez-Alamillo JC, Alarcón A, Pallardó L, Morales JM, Oliver J, Guinea G, MYVIDA Study Group.
    Transplantation; 2011 Aug 27; 92(4):426-32. PubMed ID: 21760569
    [Abstract] [Full Text] [Related]

  • 2. Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study.
    Langone AJ, Chan L, Bolin P, Cooper M.
    Transplantation; 2011 Feb 27; 91(4):470-8. PubMed ID: 21245794
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of tolerability and ability to increase immunosuppression in renal transplant patients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bilodeau JF, Montambault P, Wolff JL, Lemire J, Masse M.
    Transplant Proc; 2009 Nov 27; 41(9):3683-9. PubMed ID: 19917367
    [Abstract] [Full Text] [Related]

  • 4. Improvement in gastrointestinal and health-related quality of life outcomes after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant recipients.
    Sterneck M, Settmacher U, Ganten T, Sarrazin C, Speidel N, Broering D, Heyne N, Paulus E, Mertens M, Fischer L.
    Transplant Proc; 2014 Nov 27; 46(1):234-40. PubMed ID: 24507058
    [Abstract] [Full Text] [Related]

  • 5. Enteric-coated mycophenolate sodium: safe conversion from mycophenolate mofetil in maintenance renal transplant recipients.
    Budde K, Glander P, Diekmann F, Dragun D, Waiser J, Fritsche L, Neumayer HH.
    Transplant Proc; 2004 Mar 27; 36(2 Suppl):524S-527S. PubMed ID: 15041401
    [Abstract] [Full Text] [Related]

  • 6. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients.
    Cooper M, Deering KL, Slakey DP, Harshaw Q, Arcona S, McCann EL, Rasetto FA, Florman SS.
    Transplantation; 2009 Aug 27; 88(4):514-20. PubMed ID: 19696634
    [Abstract] [Full Text] [Related]

  • 7. Improved gastrointestinal symptoms and quality of life after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients receiving tacrolimus.
    Hwang HS, Hyoung BJ, Kim S, Oh HY, Kim YS, Kim JK, Kim YH, Kim YL, Kim CD, Shin GT, Yang CW.
    J Korean Med Sci; 2010 Dec 27; 25(12):1759-65. PubMed ID: 21165291
    [Abstract] [Full Text] [Related]

  • 8. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant recipients with gastrointestinal tract disorders.
    Darji P, Vijayaraghavan R, Thiagarajan CM, Sharma RK, Subbarao B, Pishardy R, Dakshinamurthy KV, Vijaykumar R, Abraham G, Bhaskar S, Agarwal L, Shah B, Abraham A, John M, Sampathkumar K, Das T, Umesh L, Sundar S, Ballal H, Jasuja S, Saxena S, Saha TK.
    Transplant Proc; 2008 Sep 27; 40(7):2262-7. PubMed ID: 18790208
    [Abstract] [Full Text] [Related]

  • 9. Effect of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium on maximum tolerated dose and gastrointestinal symptoms following kidney transplantation.
    Shehata M, Bhandari S, Venkat-Raman G, Moore R, D'Souza R, Riad H, Bakran A, Baker R, Needham C, Andrews C.
    Transpl Int; 2009 Aug 27; 22(8):821-30. PubMed ID: 19386081
    [Abstract] [Full Text] [Related]

  • 10. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients.
    Massari P, Duro-Garcia V, Girón F, Hernández E, Juárez F, Castro C, Toledo M, myPROMS LatAm Study Group.
    Transplant Proc; 2005 Mar 27; 37(2):916-9. PubMed ID: 15848574
    [Abstract] [Full Text] [Related]

  • 11. EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.
    Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S.
    Fundam Clin Pharmacol; 2009 Oct 27; 23(5):617-24. PubMed ID: 19656208
    [Abstract] [Full Text] [Related]

  • 12. Enteric-coated mycophenolate sodium given in combination with tacrolimus has a lower incidence of serious infections in Asian renal-transplant recipients compared with mycophenolate mofetil.
    Feng JJ, Zhang LW, Zhao P, Bow LM, Tian J.
    Int J Clin Pract Suppl; 2015 May 27; (183):1-7. PubMed ID: 26176848
    [Abstract] [Full Text] [Related]

  • 13. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil.
    Sánchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Conesa J, Barrientos A.
    Transplant Proc; 2007 Sep 27; 39(7):2194-6. PubMed ID: 17889135
    [Abstract] [Full Text] [Related]

  • 14. Sites of gastrointestinal lesion induced by mycophenolate mofetil: a comparison with enteric-coated mycophenolate sodium in rats.
    Jia Y, Wang R, Li L, Zhang Y, Li J, Wang J, Wang X, Qi G, Rong R, Xu M, Zhu T.
    BMC Pharmacol Toxicol; 2018 Jul 04; 19(1):39. PubMed ID: 29973291
    [Abstract] [Full Text] [Related]

  • 15. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R.
    Transplantation; 2006 May 15; 81(9):1290-7. PubMed ID: 16699457
    [Abstract] [Full Text] [Related]

  • 16. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Cofan F, Rosich E, Arias M, Torregrosa V, Oppenheimer F, Campistol JM.
    Transplant Proc; 2007 Sep 15; 39(7):2179-81. PubMed ID: 17889130
    [Abstract] [Full Text] [Related]

  • 17. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients.
    Burg M, Säemann MD, Wieser C, Kramer S, Fischer W, Lhotta K.
    Transplant Proc; 2009 Dec 15; 41(10):4159-64. PubMed ID: 20005359
    [Abstract] [Full Text] [Related]

  • 18. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study.
    Abbud-Filho M, Girón F, Hernández E, Juarez F, Liendo C, Novoa P, Toledo M, Myproms Latam Study Group.
    Transplant Proc; 2004 Dec 15; 36(6):1647-9. PubMed ID: 15350440
    [Abstract] [Full Text] [Related]

  • 19. A prospective analysis of the effects of enteric-coated mycophenolate sodium and mycophenolate mofetil co-medicated with a proton pump inhibitor in kidney transplant recipients at a single institute in China.
    Xu L, Cai M, Shi BY, Li ZL, Li X, Jin HL.
    Transplant Proc; 2014 Jun 15; 46(5):1362-5. PubMed ID: 24935300
    [Abstract] [Full Text] [Related]

  • 20. Changes in the small bowel of symptomatic kidney transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium.
    Bunnapradist S, Sampaio MS, Wilkinson AH, Pham PT, Huang E, Kuo HT, Anastasi B, Danovitch GM, Lo SK.
    Am J Nephrol; 2014 Jun 15; 40(2):184-90. PubMed ID: 25196230
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.